|Enrolling,Heart Failure

Power HF

The purpose of this study is to evaluate the efficacy of the medication JTT-861 administered for 12 weeks in subjects with heart failure with reduced ejection fraction (HFrEF).

Capital Area Research LLC © Copyright 2024 All rights reserved.
875 Popular Church Rd. Suite 330 Camp Hill, PA - 717.963.8389